 - Phase II Group 2 EGFRmut, de novo T790M, any c-MET, 13L antineoplastic, EGFR TKI naïve only: Advanced NSCLC patients who have not been previously treated with any therapy known to inhibit EGFR and harbor de novo T790M mutation . 